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Research on the peripheral effects of COPD has focused on physiological and structural changes.
However, different from muscular weakness or decreased physical activity, mechanical abnor-
malities of the muscular system, e.g. walking, have yet to be investigated. Our purpose was to
utilize the National Health and Nutritional Examination Survey (NHANES) dataset to determine
whetherwalking abnormalities are associatedwithCOPD severity. To determine ifwalking abnor-
malitieswere independently associatedwith COPD severity, our analysis aimed to investigate the
association of physical activity levels with COPD severity and with walking abnormalities. The
NHANES III dataset that contains data for 31,000 persons that were collected from 1988 to
1994, was used to explore the association of COPD severity on gross walking abnormalities, i.e.
limp, shuffle, etc. Logistic regression models were created using FEV1/FVC ratio, age, gender,
BMI, and smoking status as predictors of walking abnormalities and physical activity in persons
aged 40 to 90 years old. Results demonstrated a significant correlation between the presence
of walking abnormalities and severe COPD (odds ratio: 1.97; 95% CI: 1.1 to 3.5). This suggests that
disease severity can contribute to mechanical outcomes of patients with COPD. In addition,
decreased physical activity levels were significantly associatedwith all COPD severity levels with
the exception ofmild COPD. The association between altered gait and COPD statusmay be due to
the presence of physical inactivity that is present in patients with COPD. Future research direc-
tions should include investigating more closely the mechanical outcomes of persons with COPD.
ª 2010 Elsevier Ltd. All rights reserved.iomechanics Core Facility, University of Nebraska at Omaha, 6001 Dodge Street, HPER 207, Omaha,
; fax: þ1 402 554 3693.
a.edu (N. Stergiou).
0 Elsevier Ltd. All rights reserved.
Walking abnormalities are associated with COPD 81Introduction
The effects of COPD are not limited to the lungs; rather the
effects typically include “systemic and complex abnormal-
ities” affecting the peripheral systems.1 At the forefront of
these are the effects of COPD on the cardiovascular and
muscular systems. Much of the research into the effects of
COPD on themuscular system has focused on skeletal muscle
changes, including muscle atrophy, mitochondrial changes
and shifting of muscle fiber types.2e5 It is possible then that
changes in muscular structure could affect mechanical
outcomes, such as gait (walking). However, this has not been
explored in the COPD population.
COPD patients are less active than the average pop-
ulation.6e9 Using accelerometers to objectively quantify
physical activity,10e13 it is reported that one third of severe
COPD patients walk less than 15 min/day.8 Patients with the
most severe levels of COPD spend less time walking and
when they do, they walk at slower speeds.14 The decreased
physical activity seen in COPD patients is not directly
associated with disease severity. Mild COPD patients, that
have relatively normal lung function, walk approximately
50% less than healthy controls.7 Watz et al. have further
demonstrated that patients with moderate COPD have
significantly decreased physical activity levels and that
these decremented physical activity levels are not reflec-
tive of clinical tests of disease severity.15 Physical inactivity
in COPD patients is the result of many abnormalities,
including the ventilatory, musculoskeletal, neurosensory,
and cardiovascular systems. Respiratory limits to physical
activity are well established.16e18 Including dynamic
hyperinflation that worsens with activity, can impact
activity levels by constraining tidal volume, contributing to
inspiratory muscle weakness, greater neuromechanical
dissociation, and increased perception of dyspnea regard-
less of the level of severity of COPD.16e18 In addition, it has
been noted that dynamic hyperinflation contributes to
a circle of increased weakness and fatigue of respiratory
musculature; hence, causing a further impact physical
activity levels.17 Additional extrapulmonary effects of
COPD include an association of physical inactivity with
systemic inflammation and impaired left cardiac function,
as well as an increased prevalence of peripheral arterial
disease and depression.19
There is evidence that lack of physical activity contrib-
utes to peripheral muscle abnormalities and dysfunction.
Disuse of the muscular system can result in muscular
atrophy, decreased muscle strength, increased muscle
fatigability, reduced oxidative capacity, and capillary
loss.20e23 It has also been reported that activity may be
limited in COPD patients due to leg fatigue.24 Muscle
fatigue is present in mild to moderate COPD patients irre-
spective to lung function, anthropometric data, or quadri-
ceps strength.25 A contributing factor to leg fatigue could
be abnormal skeletal muscle structure, including abnormal
body cell mass alterations, muscular protein degradation
leading to muscle wasting/atrophy, impaired energy
production and metabolic performance, and increased
susceptibility to muscle weakness.2,26e33 These muscular
impairments may also lead to abnormal walking patterns;
however this has not previously been tested in COPDpatients. In support of such a concept, however, Butcher
et al. investigated balance, coordination and mobility in
COPD patients and determined that decrements in these
measures were found when compared to controls.34 These
differences were attributed to severity of disease and
lower levels of physical activity.34 Whatever the cause,
mechanical abnormalities are present in COPD patients.
Using biomechanical measures to quantify static balance
control in COPD, it has been found that COPD patients
demonstrate greater medio-lateral center of pressure
displacement and increased hip angular displacement of
the hip.35 Whether these are reflected in walking abnor-
malities remains to be determined. Interestingly, patients
with COPD also demonstrate an increase risk of falls as
compared to healthy controls, with a reported odds ratio of
4e5 times higher.36,37 Roig et al. propose a theoretical
framework to identify fall risk factors in COPD patients
which includes walking abnormalities leading to poor
mobility.38 Hence, there is a demonstrated need to inves-
tigate mechanical outcomes in COPD, including but not
limited to, walking abnormalities and balance measures.
The purpose of this study was to investigate whether or
not walking abnormalities are associated with the presence
of COPD using data from theNHANES III dataset. The National
Health and Nutritional Examination Survey (NHANES) III
dataset is a public use dataset that provides interview and
physical examination information on over 31,000 American
patients from 1988 to 1994. NHANES is a major program of
the United States National Center for Health Statistics that is
regulated by Centers for Disease Control and Prevention.
This dataset provides information regarding mechanical
outcomes of patients as well as history, physical examination
and laboratory measures, including information on the
prevalence of chronic diseases.
Using this dataset, we hypothesized that walking
abnormalities would be significantly associated with COPD
severity, due to the prevalence of peripheral muscle
abnormalities and dysfunction noted in COPD. It is thought
that these peripheral muscle changes are due to the severe
physical inactivity commonly present in patients with
COPD. Therefore, a secondary analysis conducted investi-
gating the association of subjective physical activity levels
with COPD severity. It was hypothesized that all levels of
COPD severity would be significantly associated with
decreased physical activity levels, providing further
support that physical inactivity associated with COPD is
related to walking abnormalities. The relationship between
COPD severity and activity level is neither novel nor unex-
pected; however the goal was to determine if activity level
was related to walking abnormality and which variables are
independently associated with abnormal walking patterns.
Methods and materials
Data from the NHANES III dataset were used for analysis.
Extensive details of the sampling and data collection
methodologies are available at www.cdc.gov/nchs/about/
major/nhanes/nh3data.htm. In order to account for the
sampling design that produced the NHANES dataset, all
modeling analyses and descriptive analyses where weights
are taken into account were performed using SAS SURVEY
82 J.M. Yentes et al.procedures with appropriate stratification, clustering, and
weighting variables (SAS Institute Inc., Cary, NC). These
analyses utilized data from the full six year sample as
recommended by the study documentation. These analyses
were approved as exempt by the University’s Institutional
Review Board.
Selection criteria
The original NHANES III dataset contains data on 31,311
Americans examined and surveyed from 1988 to 1994.
Patients that had completed the adult examination andwere
40e90 years old were selected for analysis (n Z 10,049).
From this selected group, subjects were eliminated from
analyses if they reported being unable to walk without help
(nZ 240). This variable is included in the physical function
evaluation given to anyone over the age of 60 years. Persons
who were coded as “no” they could not walk without help
were removed from the analyses. Finally, potential subjects
were removed if they were missing data from one of the key
variables for analyses (FEV1, FVC, walking abnormalities,
age, gender, body mass index (BMI) (n Z 1404)). In total,
8405 patient records were utilized as a sample for this
analysis.
Selection of variables
The independent variable chosen for this analysis was
classification of COPD status. Spirometric function was used
for the definition of COPD. The key parameters were the
patient’s forced expiratory volume in 1 s (FEV1) and the
ratio of the FEV1 to the forced vital capacity (FVC).
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Patients with an FEV1 to FVC ratio less than 0.7 were
classified as having COPD with severity stages determined
by classification based on their measured FEV1 values as
a percent of their predicted FEV1 values. The percent
predicted FEV1 values were calculated using equations
derived by Harkinson et al.40 for the NHANES III dataset
which calculate predicted values for each subject based on
the subject’s age, height, race, and gender. Utilizing
standards from The Global Initiative for Chronic Obstructive
Pulmonary Disease (GOLD), subjects were classified into
three COPD levels41 as well as symptoms, restrictive, and
normal classification groups (Table 1).42
Two separate models were developed. The first model
was developed to investigate the presence of walking
abnormalities in persons with COPD, using the presence of
walking abnormality as a dependent variable. ThreeTable 1 Classification of subjects based upon GOLD standards.
Classification Criteria
Severe COPD FEV1 to
Moderate COPD FEV1 to
Mild COPD FEV1 to
Symptoms FEV1 to
with sym
Restrictive FEV1 to
Normal FEV1 to
with novariables in the NHANES III dataset address walking abnor-
malities. The protocol for NHANES states that the physician
should evaluate the patient for a limp or shuffle (variable
PEP1A1). According to the NHANES instructions this must be
a chronic limp on either leg that is a current condition. If
a limp or shuffle were not present, the physician could
additionally evaluate the patient for any other walking
abnormality (variable PEP1A2). If the physician marked
“yes” to either of these conditions, the overall finding for
walking abnormalities was marked as “yes” (variable PEP1).
Only the overall finding for the locomotion variable was
used for analysis. This variable was coded as “yes, findings”
if either one or both of the other two variables (limp or
shuffle and/or other walking abnormalities) were coded as
“yes”. The second model was developed to investigate the
association of physical activity levels with COPD status. The
dependent variable for this model was a subjective
measure of physical activity. In the NHANES III Adult
Household Survey, physical activity was assessed using the
following variable, “How active are you compared with
men/women your age?” (variable HAT28). In the NHANES
dataset, the data was coded as: more active, less active,
about the same, blank but applicable, and don’t know.
Age, gender, and BMI were chosen as covariates.
Descriptive statistics for all analysis variables are presented
in Table 2. In addition to the covariates, smoking status was
added to the analysis. Data from the NHANES III Adult
Household Survey was used to create the smoking status
variable. A person was classified as “never” smoking if he/
she reported smoking fewer than all of 100 cigarettes, 20
cigars, or 20 pipefuls of tobacco in his/her lifetime. Among
persons who had smoked at least 100 cigarettes, 20 cigars,
or 20 pipefuls of tobacco, those who reported they were
not currently smoking any of cigarettes, pipes, or cigars
were classified as “former” smokers, while those who
indicated they were currently using at least one of these
three options were classified as “current” smokers.
Model development
The SAS SURVEYLOGISTIC procedure was used to generate
logistic regression models with walking abnormality and
physical activity as dependent variables and COPD classifi-
cation as the independent variable. Age, BMI, gender, and
smoking status were added to the model to control for their
effects on the outcome variable. Significance was set at an
alpha level of 0.05. For the physical activity model,
responses of “More active” and “About the same” were42
for classification
FVC ratio < 0.7 and FEV1 < 50% of predicted
FVC ratio < 0.7 and 50%  FEV1 < 80% of predicted
FVC ratio < 0.7 and FEV1  80% of predicted
FVC ratio of 0.7 to less than 1.0 and FVC < 80% of predicted
ptoms of cough, phlegm, wheeze, and/or dyspnea
FVC ratio of 0.7 to less than 1.0 and FVC > 80% of predicted
FVC ratio of 0.7 to less than 1.0 and FVC > 80% of predicted
symptoms
Table 2 Descriptive statistics for continuous and categorical variables.
Walking abnormalities No walking abnormalities
N
(Crude)
Mean SE
(Mean)
95% LCL 95% UCL N
(Crude)
Mean SE
(Mean)
95% LCL 95% UCL
Age (yrs) 837 70.04 0.87 68.31 71.78 7571 55.92 0.35 55.22 56.62
BMI 833 28.43 0.38 27.66 29.2 7564 27.22 0.13 26.95 27.48
FEV1 Meas (L) 837 2.22 0.05 2.12 2.33 7571 2.82 0.02 2.77 2.86
FEV1 Exp (L) 837 2.47 0.04 2.39 2.56 7571 3.02 0.02 2.99 3.05
FEV1 Meas/Fev1 Exp 837 0.91 0.01 0.88 0.93 7571 0.93 0 0.92 0.94
FVC (L) 837 3.09 0.06 2.97 3.22 7571 3.75 0.02 3.71 3.8
N (Crude) N (Weighted) Weighted % SE Weighted % N (Crude) N (Weighted) Weighted % SE weighted %
Male 418 2,416,712 45.41 3.14 3618 36,961,548 46.83% 0.67
Female 419 2,905,202 54.59 3.14 3953 41,967,647 53.17% 0.67
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comparison against responses of “Less active”.
Results
Using COPD status as a predictor of thewalking abnormalities
withoutcovariates, itwas found thateachCOPDclassification
compared against normal were significantly (p < 0.05) asso-
ciated to walking abnormalities. Upon adding the covariates
into themodel, SEVERE COPD (odds ratio: 2.53, 95% CI: 1.2 to
5.3) remained significantly (pZ 0.01) associated to walking
abnormalities. Thecovariatesof age (odds ratio: 1.10, 95%CI:
1.1 to 1.1) and BMI (odds ratio: 1.06, 95% CI: 1.0 to 1.1) were
also significantly (p < 0.0001) associated to walking abnor-
malities. These results are presented in Tables 3 and 4.
Furthermore, we found that SEVERE (odds ratio: 4.57,
95% CI: 2.6 to 7.9), MODERATE (odds ratio: 1.83, 95% CI: 1.3
to 2.5), SYMPTOMS (odds ratio: 1.84, 95% CI: 1.5 to 2.3),
RESTRICTIVE (odds ratio: 2.43, 95% CI: 1.9 to 3.1), BMI (odds
ratio: 1.0, 95% CI: 1.0 to 1.1), and current smoker (odds
ratio: 1.4, 95% CI: 1.2 to 1.8) were significantly (p < 0.05)
associated with less activity than other men/women their
age. Age (odds ratio: 0.97, 95% CI: 0.96 to 0.98) was
significantly (p < 0.0001) associated with the response of
more active or about the same compared to other men/
women their age. These results are presented in Table 5.
Discussion
The purpose of this study was to investigate whether or
not walking abnormalities are associated with the presenceTable 3 Logistic regression of walking abnormalities by COPD s
B SE(B) Wald X2
Intercept 3.22 0.15 437.56
COPD Overall (5 df) 44.07
Severe COPDa 1.52 0.34 20.28
Mod COPDa 0.87 0.19 21.02
Mild COPDa 0.90 0.16 30.72
Symptomsa 0.59 0.16 13.88
Restrictivea 0.88 0.21 17.15
a Reference category is normal.of COPD using data from the NHANES III dataset. It was
hypothesized that walking abnormalities would be signifi-
cantly associated with COPD severity, due to the prevalence
of peripheral dysfunction due to decrease physical activity
levels noted in COPD. The novel finding is that COPD is
related to walking abnormalities. When using a comprehen-
sive classification scheme for COPD status, a significant
association between severe COPD status and walking
abnormalities was observed. From clinical point of view,
reduced physical activity in daily life and impaired muscle
strength are the mostly likely causes. This was confirmed
as demonstrated by decreased physical activity being
significantly associatedwill all levels of COPD severity. These
results strengthen the novel findings by demonstrating the
importance of physical activity and the effect of inactivity on
walking abnormalities. Thus, questions are raised as to why
persons with severe COPD would suffer from walking
abnormalities and how is this clinically relevant?
One potential explanation for the association between
walking abnormalities and COPD severity could be the result
of decreased physical activity. It has been shown that
decreased levels of physical activity result in decreased
muscle fiber cross-sectional area, reduction inmitochondrial
density, capillary density, and amount of contractile
proteins, and increased susceptibility to assuming properties
of type II fibers.43 Skeletal muscle dysfunction present in
COPD includes loss of body cell mass and protein degrada-
tion, impaired energy production and metabolic perfor-
mance, increased susceptibility to leg fatigue, and leg
weakness leading to reduced activity.2,6e8,14,15,26e32 These
dysfunctions in the muscular system may impact walking
patterns, causing an irregular walking pattern, and furthertatus. N Z 8405 (84,234,791).
p Odds Odds 95% LCL Odds 95% UCL
<0.001
<0.001
<0.001 4.6 2.4 8.9
<0.001 2.4 1.6 3.4
<0.001 2.5 1.8 3.4
<0.001 1.8 1.3 2.5
<0.001 2.4 1.6 3.6
Table 4 Logistic regression of walking abnormalities by COPD status, age, BMI, sex, and smoking status. NZ 8389 (84,146,857)
(Note: * indicates p < 0.05).
B SE (B) Wald X2 p Odds Odds 95% LCL Odds 95% UCL
Intercept 11.0 0.66 280.3 <0.0001
COPD Overall (5 df) 9.7 0.09
Severe COPDa 0.93 0.37 6.2 0.01* 2.5 1.2 5.3
Mod COPDa 0.09 0.18 0.23 0.63 1.1 0.8 1.6
Mild COPDa 0.08 0.15 0.27 0.61 1.1 0.8 1.5
Symptomsa 0.25 0.15 2.8 0.09 1.3 1.0 1.7
Restrictivea 0.31 0.23 1.9 0.17 1.4 0.9 2.1
Age 0.10 0.00 293.4 <0.001* 1.1 1.1 1.1
Female 0.16 0.14 1.3 0.25 0.9 0.7 1.1
BMI 0.07 0.01 26.7 <0.001* 1.1 1.0 1.19
Smoking Overall (2 df) 5.7 0.06
Current Smokerb 0.27 0.23 1.4 0.24 1.3 0.8 2.1
Former Smokerb 0.14 0.17 0.66 0.42 0.9 0.6 1.2
a Reference category is normal.
b Reference category is never smoked.
84 J.M. Yentes et al.causing decreased levels of physical activity. Mechanisms
leading to reduced physical activity levels of COPD patients
have been debated, though it has been demonstrated that
activity may be limited in COPD patients due to peripheral
muscle fatigue.24 Recently, using surface electromyography
COPD patients demonstrated muscle contractile fatigue in
the rectus femoris and vastus lateralis during a 6 min walk
test of COPD patients.44 There is a growing body of evidence
that peripheralmuscle fatigue is associated to structural and
mechanical abnormalities of skeletal muscle in COPD
patients. For instance, it has been documented that skeletal
muscle contractile fatigue is affected by metabolic changes
in the skeletal muscle, redox status, systemic inflammation,
and lactic acidaccumulation.45e48 It is possible that fatigue is
the result of mitochondrial changes in COPD skeletal muscle
that are related to a greater presence of type II muscle
fibers.4,49 It has been demonstrated that sedentary controls
also demonstrate a profile of increased number of type II
muscle fibers50; therefore, it is possible disuse may be the
mechanism for mitochondrial changes in COPD patientsTable 5 Logistic regression of physical activity compared to me
and smoking status. N Z 8193 (82,225,630) (Note: * indicates p <
B SE (B) Wald X2
Intercept 2.16 0.41 27.8
COPD Overall (5 df) 103.9
Severe COPDa 1.52 0.28 29.0
Mod COPDa 0.60 0.17 12.7
Mild COPDa 0.26 0.15 2.98
Symptomsa 0.61 0.11 30.6
Restrictivea 0.89 0.12 56.8
Age 0.03 0.00 36.5
Female 0.19 0.11 2.9
BMI 0.06 0.01 59.2
Smoking Overall (2 df) 26.5
Current smokerb 0.35 0.11 11.3
Former smokerb 0.04 0.12 0.08
a Reference category is normal.
b Reference category is never smoked.leading to further decrements in activity levels. This is
further strengthened by studies that have demonstrated
that limitation in mechanical efficiency and submaximal
exercise is related to an increasedpercentage of type II fibers
and muscle disuse as opposed to peripheral muscle oxygen-
ation, respectively.51,52 Further, studies have demonstrated
positive effects of exercise training on COPD patients.53e57
These positive effects include increased muscular size,
strength, power, endurance, mitochondrial capacity, and
restoration of protein levels.58e61
Alternatively, systemic inflammation in organ systems
outside of the lungs, distinct from local pulmonary inflam-
mation may potentially be another mechanism to walking
abnormalities in COPD. This inflammation, characterized by
oxidative stress, increased levels of cytokines and leuko-
cytes, has been speculated as an underlying mechanism of
abnormal skeletal muscle structure and function in
COPD.2,3,5,45e47 Whether the abnormalities in gait in COPD
patients demonstrated in the present study result from
inactivity or from other processes remains to be determined.n/women of comparable age by COPD status, age, BMI, sex,
0.05).
p Odds Odds 95% LCL Odds 95% UCL
<0.0001
<0.001*
<0.001* 4.6 2.6 7.9
0.0004* 1.8 1.3 2.5
0.08 1.3 0.97 1.7
<0.001* 1.8 1.5 2.3
<0.001* 2.4 1.9 3.1
<0.001* 0.97 0.97 0.98
0.09 1.2 0.97 1.5
<0.001* 1.06 1.04 1.07
0.001*
0.0008* 1.4 1.2 1.8
0.77 1.03 0.8 1.3
Walking abnormalities are associated with COPD 85There are limitations associated with this study. NHANES
III dataset allows for limited investigations into the associ-
ation of COPD and walking abnormalities. Walking abnor-
malities in this dataset are poorly defined and include
overall observations of walking patterns, such as the pres-
ence of a limp or shuffle. Future studies should investigate
mechanical abnormalities using a biomechanical analysis
in order to thoroughly understand the muscular joint
responses and contributions to walking patterns. In addi-
tion, the variable used to define physical activity levels was
subjectively provided. Subjects were asked their opinion on
their activity level as compared to other adults their
same age. Use of accelerometers and pedometers provide
objective measures of physical activity.10e13
This analysis of the NHANES III dataset is the first study
that investigated whether or not walking abnormalities are
associated with COPD status. The novel finding of this study
is that COPD is related to gait abnormalities. From clinical
point of view, reduced physical activity in daily life and
impaired muscle strength are the mostly likely causes.
There has been much debate in the literature as to the
peripheral effects of COPD and whether or not mechanical
outcomes are associated with severity of the disease.
Further studies should employ objective analyses to inves-
tigate mechanical outcomes of COPD patients to determine
these associations. The biomechanical analysis of walking
abnormalities would provide procedures and measures that
can clearly examine the locomotion of COPD patients by
identifying physical deficiencies and determining the
severity of their mechanical limitations. In conclusion, this
study provides preliminary evidence that a decline in
mechanical outcomes (e.g. walking abnormalities) is asso-
ciated with persons that have severe COPD.Acknowledgements
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